News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Novartis AG (NVS) Announces China Launch for Lucentis and Galvus



1/18/2012 12:41:58 PM

January 18, 2012 -- Novartis received SFDA approval to sell Lucentis in China. Lucentis is a treatment for wet (neovascular) age-related macular degeneration (AMD), which causes blindness and vision loss, usually in people over 50. The company also announced the China launch of Galvus, an oral diabetes treatment. Galvus is a dipeptidyl peptidase IV (DPP-IV) inhibitor indicated for people with diabetes 2. More details....

Stock Symbol: (NYSE: NVS)


Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES